Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) have earned an average recommendation of "Reduce" from the nine analysts that are currently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $18.63.
Several equities research analysts have recently issued reports on IART shares. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Truist Financial decreased their price target on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Wells Fargo & Company reduced their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. JMP Securities cut their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Finally, JPMorgan Chase & Co. dropped their target price on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th.
Read Our Latest Stock Report on IART
Integra LifeSciences Trading Down 4.2%
NASDAQ IART traded down $0.53 on Friday, hitting $12.16. 954,244 shares of the company were exchanged, compared to its average volume of 1,045,717. The company's 50 day moving average price is $14.50 and its 200-day moving average price is $20.21. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The firm has a market capitalization of $944.98 million, a P/E ratio of -135.10, a price-to-earnings-growth ratio of 0.73 and a beta of 1.16. Integra LifeSciences has a twelve month low of $11.60 and a twelve month high of $32.66.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. During the same quarter in the prior year, the company earned $0.55 EPS. Integra LifeSciences's revenue for the quarter was up 3.7% on a year-over-year basis. Analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.
Institutional Trading of Integra LifeSciences
A number of institutional investors have recently modified their holdings of IART. Quadrant Capital Group LLC raised its holdings in shares of Integra LifeSciences by 5,960.9% during the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after buying an additional 1,371 shares in the last quarter. Sterling Capital Management LLC raised its position in Integra LifeSciences by 821.7% in the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after purchasing an additional 1,931 shares during the last quarter. Covestor Ltd raised its position in Integra LifeSciences by 61.8% in the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after purchasing an additional 2,071 shares during the last quarter. CWM LLC raised its position in Integra LifeSciences by 413.8% in the first quarter. CWM LLC now owns 6,664 shares of the life sciences company's stock valued at $147,000 after purchasing an additional 5,367 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in Integra LifeSciences in the fourth quarter valued at about $180,000. 84.78% of the stock is currently owned by institutional investors.
Integra LifeSciences Company Profile
(
Get Free ReportIntegra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
See Also
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
